During the past decade, University Of Chicago Medical Center; Section Of Hematology/Oncology conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 9 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Of Chicago Medical Center; Section Of Hematology/Oncology" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Novartis Pharmaceuticals" with 9 trials sponsored, "Genentech, Inc." with 6 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored and "Astellas Pharma Inc" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Of Chicago Medical Center; Section Of Hematology/Oncology" #1 collaborator was "Astellas Pharma US, Inc." with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator, "SCRI Development Innovations, LLC" with 1 trials as a collaborator and "The Leukemia and Lymphoma Society" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "University Of Chicago Medical Center; Section Of Hematology/Oncology" are "Bladder Cancer" (3 trials), "Neoplasms" (3 trials), "Cancer" (2 trials), "Colorectal Cancer" (2 trials) and "Colorectal Neoplasms" (2 trials). Many other conditions were trialed in "University Of Chicago Medical Center; Section Of Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "University Of Chicago Medical Center; Section Of Hematology/Oncology" are "Drug" (26 trials), "Biological" (5 trials), "Other" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (10 trials), "Placebo" (5 trials), "Cisplatin" (3 trials), "5-FU" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Of Chicago Medical Center; Section Of Hematology/Oncology" are 29 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University Of Chicago Medical Center; Section Of Hematology/Oncology". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in University Of Chicago Medical Center; Section Of Hematology/Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University Of Chicago Medical Center; Section Of Hematology/Oncology, 6 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".